Eli Lilly shares climbed 41% between August and December 2025 after the company closed its $6.5 billion purchase of Ventyx Pharmaceuticals on November 15, securing exclusive rights to a next-generation weight-loss therapy. Investors responded positively to the added pipeline depth—Ventyx’s Phase III candidate has demonstrated 15% average body-weight reductions in a 900-patient study—and to the deal’s accretive impact, which management said would boost adjusted EPS by 8% in 2026.

In a safety update released on January 10, the FDA reported no clear evidence linking GLP-1 receptor agonist medications to suicidal thoughts or actions. The agency reviewed nearly 2,200 adverse-event reports and trial data from over 12,000 participants, noting that reported events were too few and confounded by other factors to establish causality. A comprehensive meta-analysis of all Phase II and III trials is underway, and final conclusions are expected by mid-2026.

Eli Lilly and Nvidia will invest $1 billion over five years to launch an AI drug-discovery laboratory in the San Francisco Bay Area. Building on last October’s supercomputer deployment, the new facility will integrate Nvidia’s DGX SuperPOD technology with Lilly’s molecular biology expertise, aiming to reduce the company’s R&D cycle by up to 30% and cut early-stage molecule screening times from months to weeks.

Speaking at the JPMorgan Healthcare Conference on January 13, CFO Lucas Montarce said Eli Lilly is fully prepared to meet U.S. demand for its investigational obesity pill orforglipron, with inventory plans supporting an estimated launch volume of 100,000 patient courses in the first quarter post-approval. The drug is on track to receive regulatory clearance as early as Q2 2026, and the company has secured incremental capacity with two contract manufacturers to mitigate potential bottlenecks.